Across TCGA pan-cancer cohorts, FAM209B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM209B data layer compared with 28 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher FAM209B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM209B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KICH, SCLC, and HNSC are the cancer types where FAM209B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
HNSC	DFS	Median	All	0.136	0.625	.049	3	view →
SKCM	DFS	Median	II,III,IV	0.912	0.682	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FAM209B tumor-vs-normal RNA expression · all FAM209B data types